P-287 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPA...

Por Andrew, Dean, Ramesh, Ramanathan, Brooke, Belota, Bruce, Belanger, Deyaa, Adib, Eliel, Bayever, Li-Tzong, Chen
Publicado no Ann Oncol (2016)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer

Por Li-Tzong Chen, Teresa Macarulla, Jean-Frédéric Blanc, Beloo Mirakhur, Floris A. de Jong, Bruce Belanger, Tanios Bekaii-Saab, Jens T. Siveke
Publicado em 2019-07-01